275 related articles for article (PubMed ID: 8982770)
1. Functional consequences of the binding of MHC class II-derived peptides to MHC class II.
Feili-Hariri M; Kao H; Mietzner TA; Morel PA
Int Immunol; 1996 Dec; 8(12):1857-65. PubMed ID: 8982770
[TBL] [Abstract][Full Text] [Related]
2. A peptide binding motif for I-Eg7, the MHC class II molecule that protects E alpha-transgenic nonobese diabetic mice from autoimmune diabetes.
Gregori S; Trembleau S; Penna G; Gallazzi F; Hammer J; Papadopoulos GK; Adorini L
J Immunol; 1999 Jun; 162(11):6630-40. PubMed ID: 10352280
[TBL] [Abstract][Full Text] [Related]
3. T cell reactivity to MHC class II-bound self peptides in systemic lupus erythematosus-prone MRL/lpr mice.
Suh CH; Freed JH; Cohen PL
J Immunol; 2003 Feb; 170(4):2229-35. PubMed ID: 12574397
[TBL] [Abstract][Full Text] [Related]
4. T cells that recognize peptide sequences of self MHC class II molecules exist in syngeneic mice.
Agrawal B; Manickasundari M; Fraga E; Singh B
J Immunol; 1991 Jul; 147(2):383-90. PubMed ID: 1649218
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and tolerogenicity of self-major histocompatibility complex peptides.
Benichou G; Takizawa PA; Ho PT; Killion CC; Olson CA; McMillan M; Sercarz EE
J Exp Med; 1990 Nov; 172(5):1341-6. PubMed ID: 1700053
[TBL] [Abstract][Full Text] [Related]
6. Self-peptides that bind with low affinity to the diabetes-associated I-A(g7) molecule readily induce T cell tolerance in non-obese diabetic mice.
Ferlin WG; Mougneau E; Hugues S; Appel H; Jang MH; Cazareth J; Beaudoin L; Schricke C; Lehuen A; Wucherpfennig KW; Glaichenhaus N
Eur J Immunol; 2004 Oct; 34(10):2656-63. PubMed ID: 15368281
[TBL] [Abstract][Full Text] [Related]
7. Peptides corresponding to CD4-interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo.
Shen X; Hu B; McPhie P; Wu X; Fox A; Germain RN; König R
J Immunol; 1996 Jul; 157(1):87-100. PubMed ID: 8683160
[TBL] [Abstract][Full Text] [Related]
8. The lack of consensus for I-A(g7)-peptide binding motifs: is there a requirement for anchor amino acid side chains?
Carrasco-Marin E; Kanagawa O; Unanue ER
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8621-6. PubMed ID: 10411925
[TBL] [Abstract][Full Text] [Related]
9. Regulation of type 1 diabetes by a self-MHC class II peptide: role of transforming growth factor beta (TGF-beta).
Mukherjee R; Chaturvedi P; Agrawal B; Singh B
Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):159-69. PubMed ID: 12887099
[TBL] [Abstract][Full Text] [Related]
10. A peptide-binding motif for I-A(g7), the class II major histocompatibility complex (MHC) molecule of NOD and Biozzi AB/H mice.
Harrison LC; Honeyman MC; Trembleau S; Gregori S; Gallazzi F; Augstein P; Brusic V; Hammer J; Adorini L
J Exp Med; 1997 Mar; 185(6):1013-21. PubMed ID: 9091575
[TBL] [Abstract][Full Text] [Related]
11. A sensitive method to detect defined peptide among those eluted from murine MHC class II molecules.
Brumeanu TD; Kohanski R; Bona CA; Zaghouani H
J Immunol Methods; 1993 Mar; 160(1):65-71. PubMed ID: 8450239
[TBL] [Abstract][Full Text] [Related]
12. The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues.
Arnold PY; La Gruta NL; Miller T; Vignali KM; Adams PS; Woodland DL; Vignali DA
J Immunol; 2002 Jul; 169(2):739-49. PubMed ID: 12097376
[TBL] [Abstract][Full Text] [Related]
13. Two MHC surface amino acid differences distinguish foreign peptide recognition from autoantigen specificity.
Basu D; Horvath S; O'Mara L; Donermeyer D; Allen PM
J Immunol; 2001 Mar; 166(6):4005-11. PubMed ID: 11238647
[TBL] [Abstract][Full Text] [Related]
14. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes.
Masteller EL; Warner MR; Ferlin W; Judkowski V; Wilson D; Glaichenhaus N; Bluestone JA
J Immunol; 2003 Nov; 171(10):5587-95. PubMed ID: 14607967
[TBL] [Abstract][Full Text] [Related]
15. Peptide analogs with different affinites for MHC alter the cytokine profile of T helper cells.
Chaturvedi P; Yu Q; Southwood S; Sette A; Singh B
Int Immunol; 1996 May; 8(5):745-55. PubMed ID: 8671663
[TBL] [Abstract][Full Text] [Related]
16. Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation.
Guéry JC; Sette A; Leighton J; Dragomir A; Adorini L
J Exp Med; 1992 May; 175(5):1345-52. PubMed ID: 1569402
[TBL] [Abstract][Full Text] [Related]
17. First signature of islet beta-cell-derived naturally processed peptides selected by diabetogenic class II MHC molecules.
Suri A; Walters JJ; Rohrs HW; Gross ML; Unanue ER
J Immunol; 2008 Mar; 180(6):3849-56. PubMed ID: 18322192
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis.
Murphy B; Magee CC; Alexander SI; Waaga AM; Snoeck HW; Vella JP; Carpenter CB; Sayegh MH
J Clin Invest; 1999 Mar; 103(6):859-67. PubMed ID: 10079107
[TBL] [Abstract][Full Text] [Related]
19. Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone.
Zügel U; Schoel B; Kaufmann SH
J Immunol; 1994 Nov; 153(9):4070-80. PubMed ID: 7523514
[TBL] [Abstract][Full Text] [Related]
20. Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus.
Fedoseyeva EV; Tam RC; Orr PL; Garovoy MR; Benichou G
J Exp Med; 1995 Nov; 182(5):1481-91. PubMed ID: 7595218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
